Japanese firm HORIBA and Indian startup SigTuple have announced a partnership to accelerate the adoption of SigTuple’s AI100 across the Indian subcontinent. SigTuple leverages artificial intelligence (AI) and robotics, to automate the error-prone and inefficient manual microscopic review of samples in laboratories.

SigTuple’s AI100 is the premier solution for AI-assisted digital pathology. Its AI-based cell classification is presented to a pathologist on a cloud platform, standardising the quality and increasing the efficiency of the pathologist multifold. Further, showcasing the microscopic view of the slide remotely drives a seamless transition from manual microscopy to digital microscopy and enables telepathology.

With a vision to replace the manual microscope in the laboratory, SigTuple’s AI100 currently automates the microscopic review of the two most common tests coming to the lab – peripheral blood smear and urine, with plans to add AI capabilities for more tests on the same platform. 

“This is one of the first, if not the first, an instance of a global medical device major getting into a distribution partnership with an Indian start-p," stated, Dr Tathagato Rai Dastidar - Founder & CEO, SigTuple. 

Dr Rajeev Gautam, Corporate Officer, HORIBA, Japan & President, HORIBA India, commented, “This strategic partnership will be built on the synergies of the complementary nature of products that SigTuple would be offering to further strengthen the HORIBA product basket. We are glad to optimise our market penetration and customer connect to make this partnership successful in India and global markets."